
Sign up to save your podcasts
Or


Oncolytic Virus Construction
Adenovirus has been explored and engineered extensively as an oncolytic virus and viral vector for gene therapy to reduce viral virulence and increase efficacy and specificity. E1A gene in adenovirus is responsible for viral replication in tumor cells and needs to be attenuated for oncolytic purpose. Coated protein modification is to increase target specificity of adenovirus to tumor cells, and thus alters viral tropism. Adenovirus can also be modified through transcriptional targeting, such as placing E1A and E1B gene under control of promoter of cyclooxygenase-2 enzyme (highly expressed in a range of cancers), or through post-transcriptional modification, such as targeting of cancer specific miRNA.
fLHg9IQl8CS5qY7vPwjA
Oncolytic Virus in vitro Validation Study
Oncolytic virus is engineered by homologous recombination from parental virus. The recombination rate is low and parental virus has growth superiority. In order to get purified engineered oncolytic virus, several rounds of plaque purification must be performed. Scientist in Creative Biolabs has developed optimal method to do the plaque purification assay for oncolytic virus engineering.
Oncolytic Virus Basis
The strategy implementation of immunotherapeutic for the treatment of cancer has gained prominence over the past decade in preclinical development and clinical practice. Traditional oncological treatments, including surgery, radiation, and chemotherapy, aim to directly remove or kill cancer cells, but receive high probability of recurrences or serious side effects. In contrast, immunotherapy seeks to enhance the host immune system's ability to eliminate cancer cells, contributing to tumor regression, antitumor immune memory formation, and ultimately durable responses.
Oncolytic Virotherapy Development for Combination Therapy with Cancer Vaccines
Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus's ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer.
Cytokine/Chemokine-expressing Oncolytic Virus
Genetic therapies, such as transfected viral vectors and immune cells, continue to display clinical responses as systemically deliverable and targeted therapeutics, with the first such strategy having been approved for cancer treatment. Most of these use cytokine transgenes.
Antitumor effect of oncolytic virus
The antitumor effect of oncolytic virus can be analyzed by calculating the tumor size, tumor weight or through in vivo imaging, such as bioluminescence imaging (BLI) and position emission tomography (PET).
Example 1: CCL5 Expressing Oncolytic Virus
The chemokine CCL5 is a RANTES, which is able to regulate upon activation and normal T cell expressed. It plays an important part in several human diseases and binds to three receptors: CCR1, CCR3, and CCR514, which are expressed on a variety of types of effector and regulatory T cells. It is formed by both activated T lymphocytes and antigen presenting cells, and is widely chemoattractive. Recently, researchers have demonstrated that vvCCL5 (an oncolytic vaccinia virus expressing CCL5) constitutively expressing CCL5, promotes immune infiltration of mouse colorectal tumors in vivo and improves therapeutic effects. Besides, CCL5 expression also induces prolonged persistence of the virus exclusively within the tumor. What's more, further improvement of antitumor effectiveness is observed when vvCCL5 is used together with type-1-polarized dendritic cells (DC1) vaccination, along with enhanced immune cell infiltration into the tumor and an obvious T1 skewing of the infiltrating T-cells.
Plaque Purification Assay
Oncolytic virus is engineered by homologous recombination from parental virus. The recombination rate is low and parental virus has growth superiority. In order to get purified engineered oncolytic virus, several rounds of plaque purification must be performed. Scientist in Creative Biolabs has developed optimal method to do the plaque purification assay for oncolytic virus engineering.
Combination Therapy of Oncolytic Virus with Conventional Radiotherapy
Nowadays, overcoming malignant tumors is still a major research topic in the medical community. The current methods of treating tumors are mainly surgery, chemotherapy and radiotherapy. Radiosensitivity is the key to determine the success or failure of tumor radiotherapy. Finding ways to improve tumor radiosensitivity has become a research hotspot in the field of tumor therapy. Oncolytic virus therapy is a new tumor gene therapy approach that has emerged in recent years. This therapy uses genetic engineering methods to transform the virus so that the virus can selectively replicate in the tumor and produce oncolytic effects. There is no cross-tolerance between oncolytic virus therapy and traditional radiotherapy. The combined application of the two methods can achieve superposition or synergy.
With the significant progressing of scientific research and numerous ongoing pre-clinical development, messenger RNA has become a promising therapeutics modality for various indications including cancers and infectious diseases.
https://mrna.creative-biolabs.com/
From the publisher's feed